Imprime PGG modulates the functionality of immunosuppressive myeloid components of the tumor microenvironment and drives enhanced anti-tumor efficacy in combination with anti-PD1 antibody Anissa SH. Chan, Adria Jonas, Xiaohong Qiu, Katherine Fraser, Nadine Ottoson, Keith Gorden, Mark Uhlik, Jeremy Graff, and Nandita Bose. Biothera Pharmaceuticals, Inc., Eagan, MN, USA
Checkpoint inhibitor therapies (CPI) have shown great promise, albeit only in a limited percentage of patients. One of the key mechanisms behind the limited efficacy of CPI therapy is immune resistance mediated by immunosuppressive myeloid cells at the tumor microenvironment (TME), namely M2 macrophages and myeloid-derived suppressor cells (MDSCs). Multiple therapeutic interventions are being developed to target these cell types with the intention of reshaping the TME and enhancing the effector functions of the cytotoxic T cells. Imprime PGG (Imprime), a novel yeast derived β-glucan PAMP is being clinically developed as an innate immune modulator in combination with anti-PD1 antibody.
In ex vivo human and in vivo xenograft and syngeneic tumor models, Imprime has been shown to modulate the immunosuppressive tumor-associated macrophages (TAMs) and MDSCs in the spleen as well as TME to an M1 phenotype. The objective of this study was to evaluate Imprime's ability to modulate the functionality of these suppressive myeloid cells. We chose MC38 colon carcinoma model because it is highly immunogenic and anti-PD-1 antibody alone has significant efficacy which can be further increased by the combination with Imprime. TAMs from Imprime-treated MC38 tumors produced increased levels of TNF-a in response to LPS stimulation. Furthermore, in comparison to the TAMs enriched from tumors treated with anti-PD1 alone, the TAMs enriched from those treated with Imprime and anti-PD1 antibody showed lower expression of indoleamine 2,3-dioxygenase as well as reduced ability to suppress the proliferation of CD3/CD28-stimulated CD3+ splenocytes. Strikingly, the MDSCs enriched from the spleens of Imprime-treated mice also showed decreased suppressive functionality. Along with the anti-tumor T-cell immunity-enhancing changes in myeloid cells, Imprime treatment resulted in increased effector functionality of the tumor-infiltrating CD8 T cells and splenocytes. Collectively, these data show that Imprime is able to remold the immunosuppressive TME to a more functionally active one, thereby enabling the clinical effectiveness of CPI therapy.
Credits: None available.
You must be logged in and own this product in order to